Clinical Trial Update: Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluated eribulin mesylate in combination with pemetrexed versus pemetrexed alone as second-line therapy in stage IIIB/IV nonsquamous non-sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Eisai Inc. | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-04